Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings
Jacqueline S. Garcia(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Andrew M. Brunner(Harvard University), Eric S. Winer(Providence College), Stephanie Andrews(Moffitt Cancer Center), Marlise R. Luskin(Dana-Farber Cancer Institute), Yael Flamand(Dana-Farber Cancer Institute), Asad Bashey, Livius Penter(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Martha Wadleigh(Dana-Farber Cancer Institute), Ilene Galinsky(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Scott J. Rodig(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Michael Keng(University of Virginia), R. Coleman Lindsley(Harvard University), Lourdes Mendez(Beth Israel Deaconess Medical Center), Benjamin Tomlinson(University Hospitals Cleveland Medical Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Samer K. Khaled, David P. Steensma(Harvard University), Nicole Cullen(Dana-Farber Cancer Institute), Alexandra Savell(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 12
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k